Loading stock data…
NKTR
$86.46+1.42 (+1.67%)
Market ClosedLast close May 1
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nektar Therapeutics in the Healthcare sector is trading at $86.46. The stock is currently 21% below its 52-week high of $109.00, remaining 60.8% above its 200-day moving average. Technical signals show neutral RSI of 57 and bearish MACD signal, explaining why NKTR maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$86.46
Potential Upside
5%
Whystock Fair Value$90.78
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Mean target$144.25+66.8%
Range$95.00 – $185.00
Fundamentals
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.77B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-182.65%
Volume
Today's trading volume
689,763
Recent News
How The Rezpegaldesleukin Story Is Recasting The Narrative For Nektar Therapeutics (NKTR)
Nektar Therapeutics has just seen its fair value price target move from US$128.13 to US$144.25, a meaningful reset in what some models suggest the equity could be worth over time. Recent Street research links this shift to renewed focus on rezpegaldesleukin, Phase 3 planning in atopic dermatitis, and updated funding assumptions that feed into higher present value estimates. As you read on, you will see how these changing inputs shape the evolving analyst narrative and what to watch next in...
Nektar Therapeutics Shares 52-Week REZOLVE-AA Data as Rezpeg Boosts SALT ≤20 Responses in Alopecia Areata
Nektar Therapeutics (NASDAQ:NKTR) presented 52-week top-line results from a 16-week blinded treatment extension of its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin (rezpeg) in adults with severe to very severe alopecia areata, emphasizing that additional dosing beyond 36 weeks increased th
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Why Nektar Therapeutics Stock Rocked it Today
The biotech reported solid results from its investigational immunology drug in the treatment of a hair-loss disorder.
Nektar Therapeutics Adds To Its 129% Two-Month Run With Alopecia News
Shares of Nektar Therapeutics surged Monday after the company reported promising results for its experimental alopecia treatment.